An arteriovenous graft is described for minimizing arterial steal and graft thrombosis and, more particularly, an arteriovenous graft having means for controlling blood flow through the graft is provided.
Vascular access for hemodialysis is provided by subcutaneous placement of an arteriovenous graft. The arteriovenous graft comprises a tubular element made from biocompatible material, for instance, a fluoropolymer such as polytetrafluoroethylene. One end of the arteriovenous graft is connected to an artery while the other end is connected to a vein. Blood flows from the artery through the graft and into the vein. To connect the patient to a dialysis machine, two large hypodermic needles are inserted through the skin and into the graft. Blood is removed from the arteriovenous graft through one needle, circulated through the dialysis machine, and returned to the patient through the second needle. Typically, patients undergo hemodialysis approximately four hours per day, three days per week.
Problems have been experienced with the use of an arteriovenous graft. For example, “arterial steal” occurs when excessive blood flow through the arteriovenous graft “steals” blood from the distal arterial bed. Arterial steal can prevent the proper supply of blood from reaching the extremity of a patient. In addition, blood flowing through the arteriovenous graft can often reach turbulent flow rates, which then exits the arteriovenous graft and contacts the vein connected to the graft. This collision between the blood and the vein may cause the development of neointimal hyperplasia, which leads to the thickening of the vein walls and a narrowing of the vessel. As the vein narrows, flow through the arteriovenous graft decreases and blood within the graft may ultimately clot. The cessation of blood flow through the graft caused by clot formation is known as graft thrombosis.
For the foregoing reasons, there is a need for an arteriovenous graft that can minimize arterial steal and graft thrombosis. Ideally, the new arteriovenous graft will prevent high flows through the graft while it is not being used and thus reducing or eliminating the stimulus for intimal hyperplasia.
An arteriovenous dialysis access graft is provided to be implanted in a body of a subject. The arteriovenous dialysis graft comprises a flexible conduit defining a longitudinal flow passageway, the conduit having a first end portion and a second end portion. The first end portion is configured to connect to an artery of the subject and the second end portion is configured to connect to a vein of the subject such that blood flows through the longitudinal flow passageway of the conduit from the first end portion to the second end portion. A first cannulation chamber and a spaced second cannulation chamber are provided. The conduit extends through each of the first chamber and the second chamber. The first chamber is positioned between the first end portion and the second chamber, and the second chamber is positioned between the second end portion and the first chamber. A valve device is positioned between the first cannulation chamber and the second cannulation chamber for controlling fluid flow.
In one aspect, the valve device comprises an inner sleeve positioned within an outer sleeve, and an actuator in flow communication with the fluid passageway defined through the outer sleeve of the valve device. The actuator is configured to open and close the valve device when fluid is directed through the fluid passageway and against the wall portion such that the wall portion inflates so as to form a balloon that restricts the flow of blood through the arteriovenous graft. The actuator may be positioned outside of the arteriovenous graft and comprise a fluid injection port that is in fluid communication with the valve device.
In a further aspect, the outer sleeve of the valve device is more rigid than the inner sleeve and the outer sleeve maintains its shape when the respective balloon is inflated.
In one embodiment, the actuator comprises a piston that pumps the fluid to the valve device. In this aspect, the actuator comprises a fluid delivery device that delivers the fluid to the valve device for opening and closing the valve device. The fluid comprises a liquid or a gas.
In another aspect, each chamber comprises an elongated chamber body surrounding the conduit. The chamber body comprises an annular inner layer including self-sealing material surrounding the conduit. An outer layer is around the inner layer and defines a cannulation port that exposes the self-sealing material. An elongated shell is embedded in the chamber body between the inner layer of the chamber body and the outer layer of the chamber body and extends generally parallel to the longitudinal flow passageway of the conduit. The shell includes a posterior wall and a pair of sidewalls defining an open anterior portion facing the cannulation port of the chamber body. Each shell is formed of a substantially rigid material such that, when a dialysis needle is inserted through the cannulation port and the self-sealing material, the needle is inhibited or prevented from extending through the posterior or the side walls of the shell.
For a more complete understanding of the arteriovenous graft, reference should now be had to the embodiments shown in the accompanying drawings and described below. In the drawings:
The arteriovenous graft according to the present invention is for use in medical procedures requiring vascular access and, in particular, hemodialysis. The features described herein may be used with any conventional vascular access graft including such as, for example, the arteriovenous graft described by U.S. Pat. No. 9,585,998, the contents of which are hereby incorporated by reference herein in their entirety. A similar vascular access graft and application is shown and described in U.S. Pat. No. 7,833,186 and U.S. Pub. Application No. 2009/0209921, the contents of both of which are also incorporated by reference herein in their entirety. U.S. Pat. No. 8,764,698, the contents of which are hereby incorporated by reference herein in their entirety, describes various means for controlling blood flow through an arteriovenous graft. Accordingly, detailed explanations of the functioning of all of the components and use of the vascular access grafts are deemed unnecessary for understanding of the present description by one of ordinary skill in the art.
Certain terminology is used herein for convenience only and is not to be taken as a limiting. For example, words such as “upper,” “lower,” “left,” “right,” “horizontal,” “vertical,” “upward,” “downward,” “top” and “bottom” merely describe the configurations shown in the FIGs. Indeed, the components may be oriented in any direction and the terminology, therefore, should be understood as encompassing such variations unless specified otherwise. The words “interior” and “exterior” refer to directions toward and away from, respectively, the geometric center of the core and designated parts thereof. The terminology includes the words specifically mentioned above, derivatives thereof and words of similar import.
Referring now to
A valve device 20 is placed along the body portion 12 of the arteriovenous graft 10. The valve device 20 has an open position and a closed position. The valve device 20 functions in an open position for allowing blood flow through the arteriovenous graft 10 during normal hemodialysis. During hemodialysis, two hypodermic needles are inserted through the skin and into the arteriovenous graft 10. Blood is removed from the arteriovenous graft 10 using one needle, circulated through a dialysis machine and returned to the arteriovenous graft through the second needle. When hemodialysis has ended, the valve device 20 is moved from the open position (
As shown in
In order to inflate and deflate the balloon assembly 22, the valve device 20 may further comprise an injection port 26 in fluid communication with the inflatable balloon 22 via tubing 28. The injection port 26 may be subcutaneously implanted with the arteriovenous graft 10. The injection port 26 defines a target area configured to receive a hypodermic needle (not shown) for injecting fluid into, or withdrawing fluid from, the balloon 22. Fluid to inflate the balloon 22 travels from the injection port 26 through the tubing 28 and into the balloon 22. The fluid used to inflate the balloon 22 may be, for example, a gas or a liquid. In one embodiment, a saline solution may be injected into the injection port 26 for inflating the balloon 22 after hemodialysis has ended. Although the injection port 26 is shown in one embodiment as being subcutaneously implanted with the arteriovenous graft 10, it is understood that the injection port 26 and at least a portion of the associated tubing 28 may extend externally of the skin surface for facilitating fluid injection or removal from the balloon 22 (
A valve device 20 as described hereinabove is positioned between the cannulation chambers 38. As schematically shown in
Referring to
As seen in
The arteriovenous graft systems as described herein have many advantages, including preventing or minimizing arterial steal and graft thrombosis. In particular, the arteriovenous graft systems are designed to prevent or minimize blood flow through the graft when hemodialysis is not occurring. Reducing or stopping blood flow through the arteriovenous graft when hemodialysis is not occurring may also prevent the graft from leaking when the hypodermic needles used to carry out hemodialysis are removed from the graft.
Although the present invention has been shown and described in considerable detail with respect to only a few exemplary embodiments thereof, it should be understood by those skilled in the art that I do not intend to limit the invention to the embodiments since various modifications, omissions and additions may be made to the disclosed embodiments without materially departing from the novel teachings and advantages of the invention, particularly in light of the foregoing teachings. For example, the present invention is suitable for use in a number of vascular access devices and applications. Accordingly, we intend to cover all such modifications, omission, additions and equivalents as may be included within the spirit and scope of the invention as defined by the following claims. In the claims, means-plus-function clauses are intended to sticker the structures described herein as performing the recited function and not only structural equivalents but also equivalent structures. Thus, although a nail and a screw may not be structural equivalents in that a nail employs a cylindrical surface to secure wooden parts together, whereas a screw employs a helical surface, in the environment of fastening wooden parts, a nail and a screw may be equivalent structures.
This application is related to U.S. provisional application No. 62/479,782, filed Mar. 31, 2017, entitled “ARTERIOVENOUS GRAFT FOR MINIMIZING ARTERIAL STEAL AND GRAFT THROMBOSIS”, naming Shawn M. Gage and Jeffrey H. Lawson as the inventors. The contents of the provisional application are incorporated herein by reference in their entirety, and the benefit of the filing date of the provisional application is hereby claimed for all purposes that are legally served by such claim for the benefit of the filing date.
Number | Date | Country | |
---|---|---|---|
62479782 | Mar 2017 | US |